dispatches from DCAT Week '16
AAI and CML rebrand as Alcami
“I’m very excited to announce today here in NYC … from today on we will go by the name Alcami,” said Stephan Kutzer said at a press conference during DCAT Week 16’*. “It is a very exciting time for us.”
While the companies originally joined in late 2013 in order to offer analytical testing and development services for APIs with oral solid and parenteral dose finished product capacity, the companies believe the new unified identity will provide customers with a greater outsourcing offering.
The company is headed by a new leadership team, as well as a new commercial team. Additionally, most of the operational organization has been changed.
Kuzer stressed not only the company’s new name, but the period at the end.
“There is something to be said about this period,” he said. “It comes down to end-to-end services in the pharma industry.”
But why Alcami?
Alcami is another way of saying for AAI, CML, according to Kutzer - It is pays homage to the company’s past, while looking towards the future.
“It’s about transformation of an organization, of a service,” he added.
According to Kutzer, the company has “very interesting, prosperous growth plans.”
This growth will be driven by the company’s end-to-end services; however, Kutzer notes that individual services are available as well, as everything can also be done independently.
Kutzer also noted the companies US-base as a key to Alcami’s past and future success.
“There’s a lot of interest in local services,” he said. “We are a US based manufacturing player, and that is a key advantage.”
Alcami will provide drug substance and drug development capabilities from solid state chemistry to formulation.
The company will also be relocating from its St. Louis Analytical Testing Services to a new facility at the Cortex innovation Center.
*DCAT Week is hosted by the Drug, Chemical & Associated Technologies Association (DCAT), a not-for-profit, member-supported, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies.
